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ABSTRACT
The paper describes the use of frequentist and Bayesian shared-parameter joint 
models of longitudinal measurements of prostate specific antigen (PSA) and the 
risk of prostate cancer (PCa). The motivating dataset corresponds to the screening 
arm of the Spanish branch of the European Randomized Screening for Prostate 
Cancer (ERSPC) study. The results show that PSA is highly associated with the risk 
of being diagnosed with PCa and that there is an age-varying effect of PSA on PCa 
risk. Both the frequentist and Bayesian paradigms produced very close parameter 
estimates and subsequent 95% confidence and credibility intervals. Dynamic esti-
mations of disease-free probabilities obtained using Bayesian inference highlight 
the potential of joint models to guide personalized risk-based screening strategies.
1. INTRODUCTION
Joint models for longitudinal and time-to-event data are increasingly used to assess 
relationships between serial measurements of one or several markers and time to 
an event of interest. Joint models were introduced during the 90s (Faucett and 
Thomas, 1996; Wulfsohn and Tsiatis, 1997) and since then have been applied to a 
great variety of studies in epidemiological and biomedical areas. In turn, these stud-
ies have fed a wide methodological research on the subject, with models focused on 
event times, longitudinal patterns, or both (Neuhaus et al. (2009) and Tsiatis and 
Davidian (2004) are excellent reviews up to date).
In a setting of dependent longitudinal and time-to-event data, shared-parameter 
models consider that the longitudinal and survival processes depend jointly on a 
common set of random effects. Given the random effects, the two processes are 
assumed independent. Shared-parameter models allow one to quantify the effect of 
the underlying longitudinal outcome on the risk of an event, and obtain individual-
ized time-dynamic predictions. Recently, Rizopoulos has made a great contribution 
facilitating the use of the joint modeling methodology, first by means of an overview 
of the theory and applications of joint modeling (Rizopoulos, 2012) and secondly by 
developing the JM (Rizopoulos, 2010) and JMbayes (Rizopoulos, 2013) R packages for 
the frequentist and Bayesian shared-effects’ approaches, respectively.
cuaderno_205_5.indd   712 20/05/15   10:33
713
Number of visits per subject
1 2 3 ≥ 4 Overall
Sample size (%) 573 (23.7) 1499 (62.1) 293 (12.1) 50 (2.1) 2415 (100.0)
PSA descriptive
Mean 2.40 1.40 1.92 5.46 1.78
StDev 5.67 1.67 2.25 2.79 3.20
Min 0.00 0.00 0.00 0.50 0.00
1st Q 0.60 0.60 0.60 3.79 0.63
Median 1.10 1.00 1.10 4.69 1.06
3rd Q 2.20 1.67 2.44 6.28 1.95
Max 68.90 42.30 20.36 15.53 68.90
PCa diagnosed (%) 51 (44.0) 50 (43.1) 13 (11.2) 2 (1.7) 116 (100.0)
Table 1. Distribution of the subjects in the screening arm of the Spanish ERSPC study, descriptive 
statistics of the PSA measurements and distribution of the PCa diagnosed cases, stratified by the 
number of visits and overall.
Proust-Lima and Taylor (2009) assessed the prognostic value of longitudinal PSA 
measurements as a marker of PCa progression, in patients treated with radiother-
apy. Joint modeling is an interesting approach that allows to illustrate how classical 
and Bayesian statistics can be combined to reach a complex goal, taking advantage 
of the strengths of both paradigms. The goal of the paper is to show, from both 
approaches, how shared-parameter joint models can be used to incorporate past 
and current PSA levels into a predictive model of PCa, in a screening setting.
2. ERSPC STUDY AND DATA DESCRIPTION
Our motivating dataset consists of the screening arm of the Spanish subset of the 
European Randomized Screening for Prostate Cancer (ERSPC) study (Luján et al., 
2012). The ERSPC study is a multicenter trial initiated in 1991 in the Netherlands and 
Belgium, with six more European countries joining during the 90s. The objective of the 
ERSPC was to evaluate whether PCa screening with PSA reduces PCa specific mor-
tality in asymptomatic men. The Spanish subset recruited 4278 individuals between 
February 1996 and June 1999, aged 45 to 71 years, of whom 2415 were assigned to the 
screening arm and the remaining to the control arm. Those screened were given a 
blood test to measure PSA levels. Table 1 summarizes the description of the data.
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The variable of interest in the longitudinal analysis is PSA, ranging from 0.00 to 68.90 
ng/ml with mean and median 1.78 and 1.06 ng/ml., respectively (see Table 1). The 
original PSA variable was highly skewed to the right. A double log transformation of 
PSA was necessary to obtain a satisfactory symmetric distribution. We defined the 
LLP SA variable as the log(1+log(1+ P SA)). Figure 1 shows the time-plots of LLP SA 
according to presence or absence of PCa diagnosis.
Figure 1. LLPSA profiles versus time (age in years) for men who developed PCa during follow-up 
(top) and for 116 randomly selected men without a PCa diagnosis (bottom), participants in the 
screening arm of the Spanish ERSPC study.
We defined the time-to-event, T, as the time elapsed from the protocol screening 
start (age 45) to diagnosis of prostate cancer. We estimated that more than 90% of 
patients were prostate cancer free at age 80 years. In particular 116 men (4.8%) 
were diagnosed with PCa (median time, over age 45, equal to 17.32 years) and the 
remaining 2,299 men (95.2%) contributed to the study as right-censored data.
3. MODEL PROPOSAL
For the i-th subject, i = 1, … , n, denote by mi(t) the true LLPSA value at time t (i.e. at 
age 45 + t) and by  the whole longitudinal history of the 
true marker levels up to time t. The observable data for the i-th subject at the spe-
cific occasions tij at which measurements were taken, consists of the observed lon-
gitudinal LLPSA profile {yij = LLPSAij = log(1 + log(1 + P SAij)), j = 1, ... , ni}. Let yi(t) be 
the hypothetical observed value of LLPSA at time t which is assumed to deviate from the 
true value mi(t) by a certain error measurement εi(t) in such a way that yi(t) = mi(t) + εi(t) 
holds.
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The joint model that we propose binds a linear mixed-effects model for the longitu-
dinal part and a relative risk survival model for the time to PCa diagnosis, which 
incorporates the true historical subject profile of the longitudinal process 
(Rizopoulos, 2012). The survival submodel is based on the Weibull distribution due 
to its flexibility for representing different types of risks. To the best of our knowledge, 
this is the first time that a straightforward shared-parameter joint model of PSA and 
age at PCa diagnosis is fitted, in a screening setting, with the objective of exploring 
if longitudinal PSA measurements may orientate a personalized risk-based screen-
ing. The joint model is specified as
(1)
where  denotes the hazard function, 
T* denotes the true event time, and
is the vector containing all parameters, random effects and hyperparameters asso-
ciated with the individual i. For the longitudinal submodel, (β0, β1)T and (bi0, bi1)T are 
the fixed and the random effects for the intercept and the slope term, respectively, 
and εij the error term for the i-th subject at the j-th measurement with (εij | σ) ~ Ɲ (0, σ2); 
furthermore we assume that both random effects given σb0, σb1 and their correlation 
coefficient, ρb0 b1, follow a bivariate normal distribution with a mean of zero and an 
unstructured co variance matrix. For the survival submodel, the baseline hazard is 
given by h0(t | λ) = λ tλ−1, where λ is the shape parameter; w1 = a1 × y1 is a covariate 
which describes the interaction between the age, a1, and the LLP SA measurement, 
y1, at first visit, respectively; (γ0, γ1)T are the regression coefficients for the baseline 
hazard and the w1 interaction. Finally, α stands for the association parameter 
assessing the relationship between the longitudinal and the survival submodels.
Since preliminary analysis for joint model (1) showed a large correlation between bi0 
and bi1 we discarded the slope random effect and restrict posterior analyses, both 
frequentist and Bayesian, interpretations and conclusions to the following model
(2)
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4. ESTIMATION PROCEDURE, RESULTS AND INTERPRETATION
In the frequentist approach, the joint model expression in (2) was fitted through the 
jointModel function, implemented in the R package JM (Table 2). The estimates 
reflect a strong positive association between PSA values and risk of PCa, and allows 
estimation of the impact of different increments of PSA at specific PSA values.
Parameters Value 95% Conf. Int.
Longitudinal Submodel
β0 0.369 (0.351, 0.388)
β1 0.014 (0.013, 0.015)
σ2 0.011 (0.011, 0.012)
σ2b0  0.050 (0.044, 0.057)
Survival Submode
γ0 -13.706 (-15.299, -12.113)
γ1 -0.068 (-0.107, -0.028
λ 1.887 (1.459, 2.315)
Association
α 7.207 (6.041, 8.372)
Table 2. Joint model estimates for frequentist analysis of PCa diagnosis and longitudinal PSA values.
Similar results are obtained when estimating the full vector of uncertainties in the 
model, , from a Bayesian perspective, by using non-informative distribu-
tions as a priors and the common prior distribution given by
Computations were carried out using the statistical software WinBUGS (Lunn et al., 
2000) and R-package JMbayes.
The proposed methodology allows to dynamically estimate disease-free prob-
abilities. Figure 2 is an illustration of these updated survival probabilities 
based on the observed longitudinal subject-specific marker profile available 
up to date.
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Figure 2. LLPSA longitudinal trajectories and dynamic PCa free survival probabilities (with 95% 
pointwise credible intervals at each time point) for a patient after their first to fourth successive 
PSA measurements.
5. DISCUSSION
In this study, using data from the Spanish arm of the ERSPC study, we have esti-
mated a joint model of longitudinal measurements of PSA and time to diagnosis of 
PCa. Our model overcomes the limitations of simpler statistical tools because it 
accounts for a) the effect of PSA as an endogenous time-dependent covariate meas-
ured with error and b) the non-random dropout that results when an individual is 
diagnosed with PCa. In particular, we used both the frequentist and the Bayesian 
approaches, and built a shared-parameter joint model that combined some base-
line covariates and longitudinal PSA values to predict PCa incidence. The resulting 
model is consistent with the literature and clinical knowledge. This work can be 
considered a first step that should be followed by a more comprehensive modeling 
process accounting for additional predictive factors measured over time, e.g. pros-
tate volume or previous biopsy status (Roobol et al., 2012).
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